2017 Immuno-Oncology Symposium

Marie-Andree Forget, PhD, The University of Texas MD Anderson Cancer Center, presenting Abstract #138, "The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center"

Orlando, FL - 2017 Clinical Immuno-Oncology Symposium - Marie-Andree Forget, PhD, The University of Texas MD Anderson Cancer Center, presenting Abstract #138, "The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center," during Oral Abstract Session A at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium here today, Thursday, February 23, 2017. The conference, which is a collaboration between the American Society of Clinical Oncology and Society for Immunotherapy of Cancer, is focused on clinical and translational research in immuno-oncology and the implications for clinical care. Photo by © ASCO/Luke Franke 2017